Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.3
3.2
Journals
Life
Special Issues
Monkeypox Outbreak: Epidemiological, Clinical and Therapeutic Updates
share announcement

Monkeypox Outbreak: Epidemiological, Clinical and Therapeutic Updates

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Epidemiology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 2941

Special Issue Editor

Dr. Giuseppe Bruno

E-Mail
Guest Editor
Infectious Diseases Unit, San Giuseppe Moscati Hospital, Taranto, Italy
Interests: infectious diseases; monkeypox; antiviral treatment; HIV; COVID-19; emerging infectious diseases; hepatitis viruses

Special Issue Information

Dear Colleagues,

The monkeypox (MPX) outbreak in 2022 was declared a global health emergency on 22 July 2022 by the World Health Organization, raising the alert for this infection to the highest level. According to the latest updates, over 25,000 cases of MPX have been confirmed since May 2022, mainly in young males. From the outset, MPX infection was characterized by polymorphic clinical manifestations and, in rare cases, a severe clinical course, leading to hospitalization and death. Although the number of new cases has drastically reduced in recent weeks, the alert remains high.

This Special Issue intends to update and highlight the epidemiology, clinical manifestations and therapeutic advances towards MPX infection. Particular focus will also be placed on possible prevention strategies, including risk education, vaccination campaigns and activities to prevent stigma.

Dr. Giuseppe Bruno
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • monkeypox
  • epidemiology updates
  • sexually-transmitted diseases
  • tecovirimat
  • cidofovir
  • vaccines

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

15 pages, 667 KiB  
Review
Antivirals against Monkeypox (Mpox) in Humans: An Updated Narrative Review
by Giuseppe Bruno and Giovanni Battista Buccoliero
Life 2023, 13(10), 1969; https://doi.org/10.3390/life13101969 - 26 Sep 2023
Cited by 5 | Viewed by 1569
Abstract
As of 29 August 2023, a total of 89,596 confirmed cases of Mpox (monkeypox) have been documented across 114 countries worldwide, with 157 reported fatalities. The Mpox outbreak that transpired in 2022 predominantly affected young men who have sex with men (MSM). While [...] Read more.
As of 29 August 2023, a total of 89,596 confirmed cases of Mpox (monkeypox) have been documented across 114 countries worldwide, with 157 reported fatalities. The Mpox outbreak that transpired in 2022 predominantly affected young men who have sex with men (MSM). While most cases exhibited a mild clinical course, individuals with compromised immune systems, particularly those living with HIV infection and possessing a CD4 count below 200 cells/mm3, experienced a more severe clinical trajectory marked by heightened morbidity and mortality. The approach to managing Mpox is primarily symptomatic and supportive. However, in instances characterized by severe or complicated manifestations, the utilization of antiviral medications becomes necessary. Despite tecovirimat’s lack of official approval by the FDA for treating Mpox in humans, a wealth of positive clinical experiences exists, pending the outcomes of ongoing clinical trials. Brincidofovir and cidofovir have also been administered in select cases due to the unavailability of tecovirimat. Within the scope of this narrative review, our objective was to delve into the clinical attributes of Mpox and explore observational studies that shed light on the utilization of these antiviral agents. Full article
(This article belongs to the Special Issue Monkeypox Outbreak: Epidemiological, Clinical and Therapeutic Updates)
►▼ Show Figures

Figure 1

Other

Jump to: Review

7 pages, 414 KiB  
Brief Report
Mpox Virus: Control of In-Hospital Occupational Transmission Experience from a Tertiary Level Hospital in Milan, Italy
by Angelo Roberto Raccagni, Nicola Gianotti, Matteo Moro, Davide Mileto, Victoria Gordo Perez, Antonella Castagna and Silvia Nozza
Life 2023, 13(8), 1705; https://doi.org/10.3390/life13081705 - 8 Aug 2023
Cited by 1 | Viewed by 860
Abstract
Mpox has caused a global outbreak since May 2022, particularly affecting people belonging to key populations, but cases among healthcare providers have been reported. The aim of this work is to present the experience of the Infectious Diseases Unit of San Raffaele Scientific [...] Read more.
Mpox has caused a global outbreak since May 2022, particularly affecting people belonging to key populations, but cases among healthcare providers have been reported. The aim of this work is to present the experience of the Infectious Diseases Unit of San Raffaele Scientific Institute, Milan, Italy with respect to infection control and prevention of mpox occupational transmission. Between May–November 2022, 140 individuals were diagnosed with mpox and six required hospitalization. Overall, 12 medical doctors and 22 nurses provided care to people with mpox. A hospital policy aimed at controlling viral transmission was implemented in May 2022. Protective equipment was used for all healthcare providers. One accidental puncture occurred with a scalpel contaminated with blood from a mpox viremic individual (mpox plasma cycle threshold = 36); no mpox related symptoms were observed and mpox testing ruled out transmission. Six months following exposure, neutralizing antibodies were not detectable, ruling out contagion. Overall, we observed no mpox transmission among healthcare workers, despite the number of visits and procedures performed, including bodily-fluids sampling, and even following puncture with contaminated blood. Hospital preparedness for the management of new infectious disease outbreaks, with rapid implementation of policies aimed at controlling infection, is paramount to avoid occupational transmission. Full article
(This article belongs to the Special Issue Monkeypox Outbreak: Epidemiological, Clinical and Therapeutic Updates)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop